In breast cancer, concomitant administration of a CHK1 inhibitor and olaparib restored the sensitivity of BRCA1-deficient resistant triple negative breast cancer (TNBC) cells (Moustafa et al., 2021). Here, BRCA1 is linked to breast carcinoma.